Download MendeleyOptimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors.
Otake, K., Hara, Y., Ubukata, M., Inoue, M., Nagahashi, N., Motoda, D., Ogawa, N., Hantani, Y., Hantani, R., Adachi, T., Nomura, A., Yamaguchi, K., Maekawa, M., Mamada, H., Motomura, T., Sato, M., Harada, K.(2024) J Med Chem 67: 3741-3763
- PubMed: 38408347
- DOI: https://doi.org/10.1021/acs.jmedchem.3c02171
- Primary Citation of Related Structures:
8XGK, 8XGV - PubMed Abstract:
In research focused on protein-protein interaction (PPI) inhibitors, the optimization process to achieve both high inhibitory activity and favorable physicochemical properties remains challenging. Our previous study reported the discovery of novel and bioavailable Keap1-Nrf2 PPI inhibitor 8 which exhibited moderate in vivo activity in rats. In this work, we present our subsequent efforts to optimize this compound. Two distinct approaches were employed, targeting high energy water molecules and Ser602 as "hot spots" from the anchor with good aqueous solubility, metabolic stability, and membrane permeability. Through ligand efficiency (LE)-guided exploration, we identified two novel inhibitors 22 and 33 with good pharmacokinetics (PK) profiles and more potent in vivo activities, which appear to be promising chemical probes among the existing inhibitors.
Organizational Affiliation:
Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
